BiotechTube
Evolva Holding SA

Evolva Holding SA

EVE.SWPhase 2
Reinach, SwitzerlandFounded 2004evolva.com

Evolva was a publicly traded company that leveraged synthetic biology and precision fermentation to produce high-value compounds for the health, nutrition, and wellness markets. Its key commercial and development-stage products included resveratrol, nootkatone, and vanillin. Following severe financial distress in 2023, the company sold its main business units, underwent liquidation proceedings, and was delisted, marking the end of its operations as an independent entity.

Market Cap
$5.9M
Pipeline
1
drug candidates
Patents
—
Publications
—

AI Company Overview

Evolva was a publicly traded company that leveraged synthetic biology and precision fermentation to produce high-value compounds for the health, nutrition, and wellness markets. Its key commercial and development-stage products included resveratrol, nootkatone, and vanillin. Following severe financial distress in 2023, the company sold its main business units, underwent liquidation proceedings, and was delisted, marking the end of its operations as an independent entity.

Metabolic HealthNutritionVector Control

Technology Platform

Utilizes synthetic biology and precision fermentation to engineer yeast strains for the sustainable production of high-value, nature-inspired ingredients.

Pipeline

1
1 drug in pipeline
DrugIndicationStageWatch
EV-077 + PlaceboType 2 DiabetesPhase 2

Opportunities

For the acquirers of Evolva's assets (OQ Chemicals, LAVVAN), the opportunity lies in leveraging the developed fermentation technology and commercial groundwork to achieve scalable, profitable production of resveratrol, nootkatone, and L-Arabinose in growing markets for natural ingredients.

Risk Factors

Evolva's collapse was driven by an inability to scale production profitably, high cash burn, and failure to secure sufficient capital, highlighting the extreme execution and financial risks in capital-intensive industrial biotechnology.

Competitive Landscape

Competed directly with synthetic biology firms like Amyris and Ginkgo Bioworks, as well as traditional agricultural extract and chemical synthesis companies. Differentiation through specific molecule focus was insufficient to overcome scale-up challenges and competitive pressures.